A phase I trial of XEN 1101 for the treatment of epilepsy
Phase of Trial: Phase I
Latest Information Update: 28 Apr 2017
At a glance
- Drugs XEN 1101 (Primary)
- Indications Epilepsy
- Focus Adverse reactions; First in man
- Sponsors Xenon Pharmaceuticals
- 28 Apr 2017 New trial record
- 26 Apr 2017 According to a Xenon Pharmaceuticals media release, the company expects pharmacodynamics read-out from this trial in the first quarter of 2018.
- 26 Apr 2017 According to a Xenon Pharmaceuticals media release, the company anticipates an Investigational New Drug (IND) application or IND equivalent for XEN-1101 to initiate this phase I trial in the fourth quarter of 217.